RNA (STOCKS)
Atrium Therapeutics, Inc. Common Stock
$13.300000
+0.590000 (+4.64%)
Prev close: $12.710000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- —
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $227.62M
- Employees
- 391
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $18.76M |
| Benefits Costs and Expenses | $703.39M |
| Costs And Expenses | $703.39M |
| Nonoperating Income/Loss | $61.31M |
| Operating Expenses | $764.70M |
| Research and Development | $559.16M |
| Other Operating Expenses | $205.54M |
| Operating Income/Loss | -$745.94M |
| Income/Loss From Continuing Operations After Tax | -$684.63M |
| Income/Loss From Continuing Operations Before Tax | -$684.63M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$684.63M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$684.63M |
| Net Income/Loss Available To Common Stockholders, Basic | -$684.63M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.97 |
| Diluted Earnings Per Share | -$4.97 |
| Basic Average Shares | 137,710,000 |
| Diluted Average Shares | 137,710,000 |
| Assets | $1.96B |
| Current Assets | $1.80B |
| Prepaid Expenses | $36.46M |
| Other Current Assets | $1.76B |
| Noncurrent Assets | $159.58M |
| Fixed Assets | $23.33M |
| Other Non-current Assets | $136.25M |
| Liabilities | $269.45M |
| Current Liabilities | $195.45M |
| Accounts Payable | $12.40M |
| Other Current Liabilities | $183.04M |
| Noncurrent Liabilities | $74.00M |
| Equity | $1.69B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.69B |
| Liabilities And Equity | $1.96B |
| Net Cash Flow From Operating Activities | -$650.44M |
| Net Cash Flow From Operating Activities, Continuing | -$650.44M |
| Net Cash Flow From Investing Activities | -$38.04M |
| Net Cash Flow From Investing Activities, Continuing | -$38.04M |
| Net Cash Flow From Financing Activities | $850.99M |
| Net Cash Flow From Financing Activities, Continuing | $850.99M |
| Exchange Gains/Losses | $137.00K |
| Net Cash Flow | $162.65M |
| Net Cash Flow, Continuing | $162.51M |
| Comprehensive Income/Loss | -$684.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$684.97M |
| Other Comprehensive Income/Loss | -$340.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$340.00K |